JP5382692B2 - 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 - Google Patents

抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 Download PDF

Info

Publication number
JP5382692B2
JP5382692B2 JP2008524791A JP2008524791A JP5382692B2 JP 5382692 B2 JP5382692 B2 JP 5382692B2 JP 2008524791 A JP2008524791 A JP 2008524791A JP 2008524791 A JP2008524791 A JP 2008524791A JP 5382692 B2 JP5382692 B2 JP 5382692B2
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr3
cdr2
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008524791A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2008007648A1 (ja
Inventor
篤 杉岡
元孝 杉浦
泰 赤堀
宣宏 林
昭彦 高崎
美和 森田
仁 黒澤
万里子 住友
進 堤
恵子 小川
一起 松田
千穂 村松
乃理子 佐藤
成見 東
由範 鵜飼
和宏 鈴木
良和 黒澤
美帆 田中
葵 白石
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujita Health University
Original Assignee
Fujita Health University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujita Health University filed Critical Fujita Health University
Priority to JP2008524791A priority Critical patent/JP5382692B2/ja
Publication of JPWO2008007648A1 publication Critical patent/JPWO2008007648A1/ja
Application granted granted Critical
Publication of JP5382692B2 publication Critical patent/JP5382692B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
JP2008524791A 2006-07-10 2007-07-09 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 Expired - Fee Related JP5382692B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008524791A JP5382692B2 (ja) 2006-07-10 2007-07-09 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2006189872 2006-07-10
JP2006189872 2006-07-10
JP2007058458 2007-03-08
JP2007058458 2007-03-08
PCT/JP2007/063689 WO2008007648A1 (fr) 2006-07-10 2007-07-09 Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
JP2008524791A JP5382692B2 (ja) 2006-07-10 2007-07-09 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013197808A Division JP2014027941A (ja) 2006-07-10 2013-09-25 抗体及びその用途

Publications (2)

Publication Number Publication Date
JPWO2008007648A1 JPWO2008007648A1 (ja) 2009-12-10
JP5382692B2 true JP5382692B2 (ja) 2014-01-08

Family

ID=38923207

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008524791A Expired - Fee Related JP5382692B2 (ja) 2006-07-10 2007-07-09 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
JP2013197808A Pending JP2014027941A (ja) 2006-07-10 2013-09-25 抗体及びその用途
JP2015018098A Active JP6063494B2 (ja) 2006-07-10 2015-02-02 抗体及びその用途
JP2016156097A Pending JP2017012181A (ja) 2006-07-10 2016-08-09 抗体及びその用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013197808A Pending JP2014027941A (ja) 2006-07-10 2013-09-25 抗体及びその用途
JP2015018098A Active JP6063494B2 (ja) 2006-07-10 2015-02-02 抗体及びその用途
JP2016156097A Pending JP2017012181A (ja) 2006-07-10 2016-08-09 抗体及びその用途

Country Status (4)

Country Link
US (2) US20090203538A1 (OSRAM)
EP (2) EP2078732B1 (OSRAM)
JP (4) JP5382692B2 (OSRAM)
WO (1) WO2008007648A1 (OSRAM)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016733A2 (en) * 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7480593B2 (en) * 2005-08-03 2009-01-20 Suresh Gopalan Methods and systems for high confidence utilization of datasets
EP2069793B9 (en) 2006-08-29 2017-08-16 Oxford BioTherapeutics Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010072740A2 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
EP2379588A2 (en) 2008-12-30 2011-10-26 Cellartis AB The use of basigin-1 in stem cell and cancer applications
LT2403878T (lt) 2009-03-05 2017-10-10 E. R. Squibb & Sons, L.L.C. Pilnai žmogaus specifiniai antikūnai, skirti cadm1
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (en) * 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
WO2012031280A2 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2611464B1 (en) * 2010-09-03 2018-04-25 AbbVie Stemcentrx LLC Novel modulators and methods of use
AU2011312417B2 (en) 2010-09-29 2015-08-20 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
AU2015234335B2 (en) * 2010-09-29 2017-09-28 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN103534272B (zh) 2011-05-09 2016-05-11 株式会社英仙蛋白质科学 能够特异性识别转铁蛋白受体的抗体
CN104302321A (zh) * 2011-12-05 2015-01-21 特瑞利斯生物科学有限责任公司 可用于被动流感免疫的抗体
HUE056335T2 (hu) * 2012-01-31 2022-02-28 Regeneron Pharma ASIC1-ellenes antitestek és alkalmazásaik
JP5939855B2 (ja) * 2012-03-23 2016-06-22 国立大学法人 宮崎大学 トランスフェリン受容体抗体
US10377827B2 (en) 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US9593165B2 (en) 2012-11-08 2017-03-14 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
JP6467225B2 (ja) * 2012-11-21 2019-02-06 Ｋｍバイオロジクス株式会社 新規なヒト抗ｉｌ−１８抗体
CA2906676A1 (en) 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
LT3041507T (lt) 2013-08-26 2021-08-25 Biontech Research And Development, Inc. Nukleorūgštys, koduojančios antikūnus prieš sialil-lewis a
JP6552412B2 (ja) 2013-09-05 2019-07-31 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
PL3508502T3 (pl) 2013-09-20 2023-07-17 Bristol-Myers Squibb Company Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US9975960B2 (en) * 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
KR102401595B1 (ko) * 2014-05-09 2022-05-24 삼성전자주식회사 항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
RU2746804C2 (ru) 2014-10-10 2021-04-21 Иннейт Фарма Блокада cd73
HRP20210888T4 (hr) 2014-11-10 2024-12-06 Medimmune Limited Vezujuće molekule specifične za cd73 i njihova upotreba
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
LT3221363T (lt) * 2014-11-21 2020-08-10 Bristol-Myers Squibb Company Antikūnai prieš cd73 ir jų panaudojimas
RU2698205C2 (ru) 2014-12-18 2019-08-23 Ф. Хоффманн-Ля Рош Аг Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
EP3259288A1 (en) * 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
CN107849133B (zh) 2015-05-04 2022-08-23 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
WO2016179335A1 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
WO2016208755A1 (ja) 2015-06-25 2016-12-29 株式会社カネカ 液体注入方法
ES2791990T3 (es) * 2015-07-15 2020-11-06 Becton Dickinson Co Sistema y método para ajustar las mediciones de citometría
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2018013611A1 (en) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
WO2018027197A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
JP6996516B2 (ja) * 2016-12-13 2022-01-17 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
JP7206193B2 (ja) 2017-01-24 2023-01-17 アイ－エムエービー バイオファーマ ユーエス リミテッド 抗ｃｄ７３抗体およびその使用
CN118356488A (zh) 2017-05-30 2024-07-19 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
PT3631454T (pt) 2017-05-30 2023-11-23 Bristol Myers Squibb Co Tratamento de tumores positivos para lag-3
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
BR112020000766A2 (pt) 2017-07-14 2020-07-21 Cytomx Therapeutics, Inc. anticorpos anti-cd166 e seus usos
CA3088199A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CA3090008A1 (en) 2018-03-09 2019-09-12 Phanes Therapeutics, Inc. Anti-cd73 antibodies and uses thereof
AU2019231791B2 (en) 2018-03-09 2022-08-11 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
US11034771B2 (en) 2018-07-25 2021-06-15 I-Mab Biopharma Us Limited Anti-CD73 anti-PD-L1 bispecific antibodies
US12257340B2 (en) 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
KR102063341B1 (ko) 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP3947452A4 (en) 2019-03-29 2023-05-03 Lankenau Institute for Medical Research ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE
EP4028422A4 (en) * 2019-09-13 2024-01-10 Memorial Sloan-Kettering Cancer Center ANTI-CD371 ANTIBODIES AND THEIR USES
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4076666A1 (en) * 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
CN115135341A (zh) 2020-01-03 2022-09-30 因赛特公司 抗cd73抗体及其用途
EP4088113A4 (en) * 2020-01-12 2024-05-15 Vanderbilt University HUMAN ANTIBODIES AGAINST RIFT VALLEY FEVER VIRUS
CN111738980B (zh) * 2020-05-14 2023-08-04 北京深睿博联科技有限责任公司 一种医学影像的显示方法、计算机设备及存储介质
WO2021241729A1 (ja) * 2020-05-29 2021-12-02 ブライトパス・バイオ株式会社 抗ｃｄ７３抗体およびその用途
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
KR102887692B1 (ko) * 2021-05-21 2025-11-18 주식회사 지놈앤컴퍼니 항-bcam 항체 또는 그의 항원 결합 단편
TW202315890A (zh) * 2021-06-08 2023-04-16 德商馬克專利公司 結合cd80及/或cd86及ox40l之蛋白質
WO2023034809A1 (en) 2021-08-30 2023-03-09 Lassen Therapeutics 1, Inc. Anti-il-11rα antibodies
CN114137231B (zh) * 2022-01-29 2022-04-29 北京大有天弘科技有限公司 一种血型不规则抗体的检测试剂盒及其应用
US12187806B2 (en) 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024215624A2 (en) * 2023-04-13 2024-10-17 A & G Pharmaceutical, Inc. Antibodies and conjugates against prostaglandin f2 receptor inhibitor and uses thereof
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000000097A (ja) * 1998-06-15 2000-01-07 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ結合蛋白質、該蛋白質をコードするＤＮＡ並びに該蛋白質に対するモノクローナル抗体
WO2001096401A1 (fr) * 2000-06-14 2001-12-20 Medical & Biological Laboratories Co., Ltd. Procede de construction d'un anticorps scfv fusionne a une proteine fluorescente

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CZ292061B6 (cs) 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US8101553B1 (en) 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
DK1294769T3 (da) * 2000-06-16 2011-04-26 Human Genome Sciences Inc Antistoffer der immunspecifikt binder til BLyS
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20040259153A1 (en) * 2001-08-22 2004-12-23 Yoshikazu Kurosawa Methods for selecting biding molecule
JP4660189B2 (ja) * 2002-07-03 2011-03-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
JP4870348B2 (ja) 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
CA2573293A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
JP2006025749A (ja) 2004-07-21 2006-02-02 Kawabe:Kk ペット用引き綱
JP4942644B2 (ja) 2005-02-28 2012-05-30 株式会社抗体研究所 抗ＩｇＳＦ４抗体及びその利用
JP2006303195A (ja) 2005-04-20 2006-11-02 Sony Corp レーザモジュール
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
JP5242382B2 (ja) * 2006-04-14 2013-07-24 株式会社医学生物学研究所 エフェクター機能を有するポリペプチド変異体
EP2828339B1 (en) 2012-03-19 2018-10-31 Milliken & Company Carboxylate dyes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000000097A (ja) * 1998-06-15 2000-01-07 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ結合蛋白質、該蛋白質をコードするＤＮＡ並びに該蛋白質に対するモノクローナル抗体
WO2001096401A1 (fr) * 2000-06-14 2001-12-20 Medical & Biological Laboratories Co., Ltd. Procede de construction d'un anticorps scfv fusionne a une proteine fluorescente

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6007002261; 今井高志　他: 'ＹＡＣライブラリーのスクリーニング' 蛋白質核酸酵素 Ｖｏｌ．３８，　Ｎｏ．３, 1993, ｐ．５９１-５９９ *

Also Published As

Publication number Publication date
JP6063494B2 (ja) 2017-01-18
US20140235833A1 (en) 2014-08-21
WO2008007648A1 (fr) 2008-01-17
EP2078732B1 (en) 2015-09-16
US20090203538A1 (en) 2009-08-13
JP2015143226A (ja) 2015-08-06
JPWO2008007648A1 (ja) 2009-12-10
EP2975057A1 (en) 2016-01-20
US9388249B2 (en) 2016-07-12
EP2078732A4 (en) 2010-07-28
EP2078732A1 (en) 2009-07-15
JP2017012181A (ja) 2017-01-19
JP2014027941A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
JP6063494B2 (ja) 抗体及びその用途
JP4942644B2 (ja) 抗ＩｇＳＦ４抗体及びその利用
JP6980075B2 (ja) がん細胞特異的な抗体、抗がん剤、及びがんの検査方法
CN110382533B (zh) 特异性结合CD66c的抗体及其用途
KR20230156936A (ko) 그렘린1 길항제를 사용하여 질환을 치료하는 방법
KR101906558B1 (ko) Tspan8에 특이적인 신규 항체 및 이의 용도
CN112740043A (zh) Vista受体
BR122024015952A2 (pt) Ligação de anticorpos especificamente à cd66c e utilização dos mesmos
BR112019009771B1 (pt) Ligação de anticorpos especificamente à cd66c e utilização dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121025

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20121206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130925

R150 Certificate of patent or registration of utility model

Ref document number: 5382692

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees